Navigation Links
Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:5/24/2011

NEW YORK, May 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0511065/Retinal-Vein-Occlusion-RVO-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global RVO market. The report identifies the key trends shaping and driving the global RVO market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global RVO sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData valued the Retinal Vein Occlusion (RVO) therapeutics market in 2010 at $496m, indicating a growth rate of 29.25% between 2005 and 2010. Until the market entry of Lucentis (ranibizumab) in 2006, the RVO therapeutics market was growing at a lower rate. After the entry of Lucentis, the market registered a growth rate of 40.13% between 2006 and 2007. Up until now, Lucentis and Ozurdex have been the only approved drugs for the treatment of RVO. The late-stage clinical development pipeline consists of 50% first-in-class and 50% me-too drugs that are effective and safe for RVO patients. Once these drugs enter the market, the market will grow further at a significant rate. Therefore, GlobalData estimates that the RVO therapeutics market in 2017 will be $1.4 billion, indicating a Compound Annual Growth Rate (CAGR) of 16.08% between 2010 and 2017

Scope

The report provides information on the key drivers and challenges of the retinal vein occlusion therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) retinal vein occlusion therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as VEGF inhibitors, HMG CoA reductase inhibitors, Glucocorticoid receptor agonists, and kallikrein inhibitors.

- Analysis of the current and future competition in the seven key countries retinal vein occlusion market. Key market players covered are Allergan, Inc., Alimera Sciences, Icon Biosciences, and Regeneron Pharmaceuticals.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the retinal vein occlusion therapeutics market.

- Analysis of key recent licensing and partnership agreements in retinal vein occlusion market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global retinal vein occlusion market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global retinal vein occlusion market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global retinal vein occlusion market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Retinal Vein Occlusion Therapeutics: Introduction 6

2.1 Overview 6

2.2 Epidemiology 7

2.3 Etiology and Pathophysiology 8

2.4 Signs and Symptoms 8

2.5 Diagnosis 9

2.6 Treatment 9

2.7 GlobalData Pipeline Report Guidance 12

3 Retinal Vein Occlusion Therapeutics: Market Characterization 13

3.1 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) 13

3.2 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) 14

3.3 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – The US 15

3.4 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) – The US 16

3.5 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – France 17

3.6 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) – France 18

3.7 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – Germany 19

3.8 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) – Germany 20

3.9 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – Italy 21

3.10 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) – Italy 22

3.11 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – Spain 23

3.12 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) – Spain 24

3.13 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – The UK 25

3.14 Retinal Vein Occlusion Therapeutics Market Forecast (2010-2017) – The UK 26

3.15 Retinal Vein Occlusion Therapeutics Market Size (2005-2010) – Japan 27

3.16 Retinal vein Occlusion Therapeutics Market Forecast (2010-2017) – Japan 28

3.17 Drivers and Barriers for Retinal Vein Occlusion Therapeutics Market 29

3.17.1 Drivers for the Retinal Vein Occlusion Therapeutics Market 29

3.17.2 Barriers for Retinal Vein Occlusion Therapeutics Market 29

3.18 Opportunity and Unmet Need Analysis 30

3.19 Key Takeaway 31

4 Retinal Vein Occlusion Therapeutics: Competitive Assessment 32

4.1 Overview 32

4.2 Strategic Competitor Assessment 32

4.3 Product Profile for the Major Marketed Products in the Retinal Vein Occlusion Therapeutics Market 33

4.3.1 Lucentis (ranibizumab) 33

4.3.2 Ozurdex (dexamethasone implant) 34

4.4 Key Takeaway 35

5 Retinal Vein Occlusion Therapeutics: Pipeline Assessment 37

5.1 Overview 37

5.2 Strategic Pipeline Assessment 37

5.3 Retinal Vein Occlusion Therapeutic Pipeline – Pipeline by Clinical Phases of Development 37

5.3.1 Retinal Vein Occlusion Therapeutics – Regulatory Filing and Phase III Pipeline 37

5.3.2 Retinal Vein Occlusion Therapeutics – Phase II Pipeline 38

5.3.3 Retinal Vein Occlusion Therapeutics – Phase I Pipeline 38

5.3.4 Technology Trends Analytic Framework 39

5.4 Retinal Vein Occlusion Therapeutics Market – Clinical Pipeline by Mechanism of Action 41

5.4.1 Retinal Vein Occlusion – Promising Drugs Under Clinical Development 42

5.5 Molecule Profile for Promising Drugs Under Clinical Development 42

5.5.1 VEGF Trap Eye 42

5.5.2 IBI-20089 43

5.6 Key Takeaway 44

6 Retinal Vein Occlusion Therapeutics: Clinical Trials Mapping 45

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 45

6.2 Clinical Trials by Phase 46

6.3 Clinical Trials by Trial Status 47

6.4 Prominent Sponsors 48

6.5 Top Companies Participating in Clinical Trials 50

7 Strategic Assessment 51

7.1 Key Events Impacting the Future Market 51

7.2 Retinal Vein Occlusion Therapeutics: Implications for Future Market Competition 52

8 Retinal Vein Occlusion Therapeutics: Future Players 53

8.1 Introduction 53

8.2 Company Profiles 53

8.2.1 Allergan, Inc. 53

8.2.2 Alimera Sciences 56

8.2.3 Bayer AG 57

8.2.4 Fovea Pharmaceuticals SA 61

8.2.5 Icon Biosciences 62

8.2.6 Regeneron Pharmaceuticals 62

8.2.7 Suzuken Co.Ltd. 64

9 Licensing and Partnership Deals 66

10 Retinal Vein Occlusion Therapeutics: Appendix 67

10.1 Market Definitions 67

10.2 Abbreviations 67

10.3 Methodology 68

10.3.1 Coverage 68

10.3.2 Secondary Research 68

10.3.3 Forecasting 69

10.3.4 Primary Research 71

10.3.5 Expert Panel Validation 72

10.4 Contact Us 72

10.5 Disclaimer 72

10.6 Bibliography 72

1.1 List of Tables

Table 1: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2005–2010 13

Table 2: Retinal Vein Occlusion Therapeutics Market, Global, Forecasts ($m), 2010–2017 14

Table 3: Retinal Vein Occlusion Therapeutics Market, The US, Revenue ($m), 2005–2010 15

Table 4: Retinal Vein Occlusion Therapeutics Market, The US, Forecasts ($m), 2010–2017 16

Table 5: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2005–2010 17

Table 6: Retinal Vein Occlusion Therapeutics Market, France, Forecasts ($m), 2010–2017 18

Table 7: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2005–2010 19

Table 8: Retinal Vein Occlusion Therapeutics Market, Germany, Forecasts ($m), 2010–2017 20

Table 9: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2005–2010 21

Table 10: Retinal Vein Occlusion Therapeutics Market, Italy, Forecasts ($m), 2010–2017 22

Table 11: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2005–2010 23

Table 12: Retinal Vein Occlusion Therapeutics Market, Spain, Forecasts ($m), 2010–2017 24

Table 13: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2005–2010 25

Table 14: Retinal Vein Occlusion Therapeutics Market, The UK, Forecasts ($m), 2010–2017 26

Table 15: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2005–2010 27

Table 16: Retinal Vein Occlusion Therapeutics Market, Japan, Forecasts ($m), 2010–2017 28

Table 17: Efficacy and Safety Profile of Lucentis 34

Table 18: Retinal Vein Occlusion Therapeutics, Historical Sales of Lucentis ($m) 34

Table 19: Number (%) of Patients With ? 15 Letters Improvement from Baseline in BCVA 35

Table 20: Adverse Reactions Reported by >2% of Patients in the First Six Months 35

Table 21: Retinal Vein Occlusion Therapeutics, Marketed Products Comparison, 2010 36

Table 22: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2011 37

Table 23: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2011 38

Table 24: Retinal Vein Occlusion Therapeutics, Phase I Pipeline, 2011 38

Table 25: Retinal Vein Occlusion Therapeutics, Most Promising Drugs Under Clinical Development, 2011 42

Table 26: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2011 45

Table 27: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2011 46

Table 28: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2011 47

Table 29: Retinal Vein Occlusion Therapeutics, Overall Sponsors, 2011 48

Table 30: Retinal Vein Occlusion Therapeutics, Prominent Sponsors, 2011 49

Table 31: Retinal Vein Occlusion Therapeutics, Top Companies Participating in Clinical Trials, 2011 50

Table 32: Retinal Vein Occlusion Therapeutics, Allergan, Retinal Vein Occlusion Pipeline, 2011 55

Table 33: Allergan, Inc. Deals, 2009-2011 55

Table 34: Retinal Vein Occlusion Therapeutics, Alimera Sciences, Ophthalmology Pipeline, 2011 56

Table 35: Retinal Vein Occlusion Therapeutics, Alimera Sciences, Retinal Vein Occlusion Pipeline, 2011 56

Table 36: Alimera Sciences Deals, 2009-2011 57

Table 37: Retinal Vein Occlusion Therapeutics, Bayer AG, Ophthalmology Pipeline, 2011 59

Table 38 Retinal Vein Occlusion Therapeutics, Bayer AG, Retinal Vein Occlusion Pipeline, 2011 59

Table 39: Bayer AG Deals, 2009-2011 60

Table 40: Fovea Pharmaceuticals Deals, 2009-2011 61

Table 41: Retinal Vein Occlusion Therapeutics, Regeneron Pharmaceuticals, Ophthalmology Pipeline, 2011 63

Table 42: Retinal Vein Occlusion Therapeutics, Regeneron Pharmaceuticals, Retinal Vein Occlusion Pipeline, 2011 63

Table 43: Regeneron Pharmaceuticals Deals, 2009-2011 64

Table 44: Retinal Vein Occlusion Therapeutics, Global, Deals, 2008-2011 66

1.2 List of Figures

Figure 1: Eye Diagram Depicting Normal and Effected Blood Vessels 6

Figure 2: Recent Onset Central Retinal Vein Occlusion, Showing Extensive Hemorrhages in the Posterior Pole and Creating the "Blood and Thunder Appearance" 7

Figure 3: Peripheral Fundus View, Showing Hemorrhages Extending All Over the Fundus 7

Figure 4: Fluorescein Angiograph Showing Hypofluorescence Due to Hemorrhages in Retina 9

Figure 5: Treatment Algorithm for RVO 9

Figure 6: Preferred Treatment for Macular Edema Following BRVO 11

Figure 7: Preferred Treatment for Cystoid Macular Edema Following CRVO 11

Figure 8: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2005–2010 13

Figure 9: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2010–2017 14

Figure 10: Retinal Vein Occlusion Therapeutics Market, The US, Revenue ($m), 2005-2010 15

Figure 11: Retinal Vein Occlusion Therapeutics Market, The US, Forecast ($m), 2010–2017 16

Figure 12: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2005–2010 17

Figure 13: Retinal Vein Occlusion Therapeutics Market, France, Forecast ($m), 2010–2017 18

Figure 14: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2005–2010 19

Figure 15: Retinal Vein Occlusion Therapeutics Market, Germany, Forecast ($m), 2010–2017 20

Figure 16: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2005–2010 21

Figure 17: Retinal Vein Occlusion Therapeutics Market, Italy, Forecast ($m), 2010–2017 22

Figure 18: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2005–2010 23

Figure 19: Retinal Vein Occlusion Therapeutics Market, Spain, Forecast ($m), 2010–2017 24

Figure 20: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2005–2010 25

Figure 21: Retinal Vein Occlusion Therapeutics Market, The UK, Forecast ($m), 2010–2017 26

Figure 22: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2005–2010 27

Figure 23: Retinal Vein Occlusion Therapeutics Market, Japan, Forecast ($m), 2010–2017 28

Figure 24: Opportunity and Unmet Need in the Retinal Vein Occlusion Therapeutics Market, 2010 30

Figure 25: Retinal Vein Occlusion Therapeutics, Strategic Competitor Assessment, 2010 32

Figure 26: Retinal Vein Occlusion Therapeutics, Pipeline by Phase of Development, 2011 37

Figure 27: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, 2011 39

Figure 28: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, Description, 2011 40

Figure 29: Retinal Vein Occlusion Therapeutics, Pipeline by Mechanism of Action (%), 2011 41

Figure 30: IBI-20089 Interim Optical Coherence Tomography (OCT) results 44

Figure 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2011 45

Figure 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase (%), 2011 46

Figure 33: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status (%), 2011 47

Figure 34: Retinal Vein Occlusion Therapeutics, Overall Sponsors (%), 2011 48

Figure 35: Retinal Vein Occlusion Therapeutics, Prominent Sponsors (%), 2011 49

Figure 36: Retinal Vein Occlusion Therapeutics, Top Companies Participating in Clinical Trials, 2011 50

Figure 37: Retinal Vein Occlusion Therapeutics Market, Drivers and Restraints, 2011 51

Figure 38: Implications for Future Market Competition in the Retinal Vein Occlusion Therapeutics Market, 2011 52

Figure 39: Retinal Vein Occlusion Therapeutics Market, Pipeline by Company, 2011 53

Figure 40: GlobalData Market Forecasting Model 71

Companies MentionedAllergan, Inc.

Alimera Sciences

Bayer AG

Fovea Pharmaceuticals SA

Icon Biosciences

Regeneron Pharmaceuticals

Suzuken Co.Ltd.

To order this report:

Drug Discovery and Development Industry: Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
2. Reportlinker Adds Triple Analysis: Lymphoma, Melanoma and Peptides
3. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
4. Reportlinker Adds Advanced Digital Medical Equipment Products Market
5. Reportlinker Adds India Medical Devices Manufacturers, Distributors and Exporters Directory 2011
6. Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
7. Reportlinker Adds Orphan Drugs in Asia 2011
8. Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry
9. Reportlinker Adds The Outlook for Medical Devices in South East Asia
10. Reportlinker Adds Pharmaceutical Management of Obesity (Technical Insights)
11. Reportlinker Adds Machine-to-Machine (M2M) Communications in Healthcare 2010-20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... full year ended December 31, 2015. ... year for Vanda with the continued growth of HETLIOZ ... HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s ... U.S. product portfolio builds on this success and underscores ...
(Date:2/10/2016)... , February 10, 2016 A new report from ... - states that the Alzheimer,s disease market will more than double from ... at a Compound Annual Growth Rate (CAGR) of 11%. Canada ... Italy , Spain , the UK, and ... during the forecast period. --> Canada , ...
(Date:2/10/2016)... R.I. , Feb. 10, 2016  CVS Health ... to people living in Santa Clara County, ... Meningitis B on the Santa Clara University campus. CVS ... available to protect patients against the disease. Students at ... encouraged to get vaccinated. In addition, anyone who has ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , a ... partnered with Heart City Health Center to improve access to language ... City Health Center has provided the Elkhart community with access to high quality, ...
(Date:2/10/2016)... NY (PRWEB) , ... February 10, 2016 , ... ... compliance tracking solution, The Guard, to associations of medical professionals throughout the country. ... compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, and ...
(Date:2/10/2016)... ... , ... Emergency rooms provide emergency care to stabilize critical health issues, but ... dental emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Valley , announces that his office is now offering a variety of comprehensive ... enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. ...
Breaking Medicine News(10 mins):